- Home
- CSGS vs CDTX Comparison
CSGS vs CDTX Comparison
Compare CSGS & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGS
- CDTX
- Stock Information
- Founded
- CSGS 1994
- CDTX 2012
- Country
- CSGS United States
- CDTX United States
- Employees
- CSGS N/A
- CDTX N/A
- Industry
- CSGS EDP Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSGS Technology
- CDTX Health Care
- Exchange
- CSGS Nasdaq
- CDTX Nasdaq
- Market Cap
- CSGS 1.9B
- CDTX 1.6B
- IPO Year
- CSGS 1996
- CDTX 2015
- Fundamental
- Price
- CSGS $64.67
- CDTX $65.62
- Analyst Decision
- CSGS Buy
- CDTX Strong Buy
- Analyst Count
- CSGS 8
- CDTX 11
- Target Price
- CSGS $68.86
- CDTX $57.00
- AVG Volume (30 Days)
- CSGS 210.0K
- CDTX 468.4K
- Earning Date
- CSGS 11-05-2025
- CDTX 11-06-2025
- Dividend Yield
- CSGS 1.98%
- CDTX N/A
- EPS Growth
- CSGS 30.24
- CDTX N/A
- EPS
- CSGS 2.89
- CDTX N/A
- Revenue
- CSGS $1,208,376,000.00
- CDTX N/A
- Revenue This Year
- CSGS $3.49
- CDTX N/A
- Revenue Next Year
- CSGS $3.23
- CDTX N/A
- P/E Ratio
- CSGS $22.43
- CDTX N/A
- Revenue Growth
- CSGS 3.31
- CDTX N/A
- 52 Week Low
- CSGS $44.57
- CDTX $10.14
- 52 Week High
- CSGS $67.60
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- CSGS 53.77
- CDTX 58.37
- Support Level
- CSGS $63.11
- CDTX $61.10
- Resistance Level
- CSGS $65.85
- CDTX $65.84
- Average True Range (ATR)
- CSGS 1.30
- CDTX 3.06
- MACD
- CSGS 0.09
- CDTX -0.42
- Stochastic Oscillator
- CSGS 66.85
- CDTX 73.11
About CSGS CSG Systems International Inc.
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, the company generates revenue from the United States.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.